Holen Sie sich die Stockscreener-App
0.957
2.28%
0.0213
Schlusskurs vom Vortag:
$0.9357
Offen:
$0.9616
24-Stunden-Volumen:
304.79K
Relative Volume:
0.19
Marktkapitalisierung:
$109.36M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.58
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
-11.39%
1M Leistung:
-16.78%
6M Leistung:
-23.44%
1J Leistung:
-71.26%
1-Tages-Spanne:
$0.936
$0.9636
1-Wochen-Bereich:
$0.91
$1.08
52-Wochen-Spanne:
$0.6611
$4.20
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
0.9542 | 105.62M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.84 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.51 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.39 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
642.82 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.24 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Can machine learning forecast Fate Therapeutics Inc. recoveryBuy Opportunity Forecast for Fast Traders - Newser
What makes Fate Therapeutics Inc. stock price move sharplyHigh Conviction Stock Long-Term Summary - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Trade Opportunity Alerts - Newser
Analyzing net buyer seller activity in Fate Therapeutics Inc.Free Entry and Exit Strategy Optimizer Tool - Newser
Fate Therapeutics Inc. stock trend forecastFree Risk Controlled Picks With Real Returns - Newser
Fate Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Trapped Investors in Fate Therapeutics Inc. Await Breakout SignalWatchlist for Smart Swing Trading Updated - metal.it
Fate Therapeutics shares fall 4.52% intraday due to unspecified reasons. - AInvest
Full technical analysis of Fate Therapeutics Inc. stockSwing Trade Picks with High Potential - Newser
Fate Therapeutics shares fall 4.17% intraday after granting non-qualified stock options to a new employee. - AInvest
Fate Therapeutics CEO Makes a Notable Stock Sale! - TipRanks
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics' Strategic Talent Acquisition and Equity Incentive Program: A Catalyst for Biotech Innovation and Shareholder Value - AInvest
Fate Therapeutics reports new employee inducement awards - MarketScreener
Fate Therapeutics CEO Valamehr sells $15,396 in stock By Investing.com - Investing.com Canada
Fate Therapeutics CEO Valamehr sells $15,396 in stock - Investing.com
Cwm LLC Buys 37,290 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics (NASDAQ:FATE) Upgraded at Wall Street Zen - Defense World
Fate Therapeutics Inc. Nearing Breakout Level After BounceAccurate Technical Trend Reversal Picks Detected - metal.it
What catalysts could drive Fate Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - Jammu Links News
What is the dividend policy of Fate Therapeutics Inc. stockFree Stock Market Return Analysis - Jammu Links News
How strong is Fate Therapeutics Inc. company’s balance sheetFree Capital Efficiency Planning - Jammu Links News
How does Fate Therapeutics Inc. generate profit in a changing economyFree Stock Market Trend Analysis - Jammu Links News
Wells Fargo Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $4 - 富途牛牛
What is Fate Therapeutics Inc. company’s growth strategyUnlock exclusive stock market insights - Jammu Links News
What are Fate Therapeutics Inc. company’s key revenue driversUnlock powerful trading signals and alerts - Jammu Links News
How does Fate Therapeutics Inc. compare to its industry peersBuild a diversified portfolio for risk mitigation - Jammu Links News
Does Fate Therapeutics Inc. stock perform well during market downturnsMassive stock growth - Jammu Links News
Is Fate Therapeutics Inc. a growth stock or a value stockInvest confidently with market-leading analysis - Jammu Links News
Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases - TipRanks
How volatile is Fate Therapeutics Inc. stock compared to the marketTop Growth Tracker With Low Risk - Jammu Links News
Published on: 2025-07-30 19:50:13 - metal.it
Published on: 2025-07-30 17:10:31 - beatles.ru
Published on: 2025-07-30 08:12:45 - metal.it
How Resilient Is Fate Therapeutics Inc. Stock During Economic DownturnsDaily Smart Money Movement Monitor Activated - metal.it
Will Fate Therapeutics Inc. stock go up soonShort-Term Swing Opportunity Summary Sheet - Newser
What to expect from Fate Therapeutics Inc. in the next 30 daysFree AI Powered High Return Stock Calls - Newser
Ranking Fate Therapeutics Inc. among high performing stocks via toolsWeekly Gain Forecast with Momentum Indicators - Newser
Can Fate Therapeutics Inc. stock recover from recent declineLong Term Safe Yield Focus - metal.it
What institutional investors are buying Fate Therapeutics Inc. stockConsistently outstanding ROI - Jammu Links News
Is Fate Therapeutics Inc. stock overvalued or undervaluedAchieve fast wealth growth with smart picks - Jammu Links News
What are analysts’ price targets for Fate Therapeutics Inc. in the next 12 monthsDiscover stocks with massive upside potential - Jammu Links News
Will Fate Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsDaily Top Gainers - metal.it
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
2.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):